Cassava Sciences, Inc. (NASDAQ: SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for ...

Bearish flow noted in Cassava Sciences (SAVA) with 3,180 puts trading, or 1.8x expected. Most active are 11/22 weekly 13 puts and 11/22 weekly 25 puts, with total volume in those strikes near 1,000 ...

Cassava Sciences (NASDAQ:SAVA) has tapped Freda Nassif as chief commercial officer, effective Nov. 18, 2024. Ms. Nassif is an ...

Panax ginseng shows highest effectiveness in treating Alzheimer's. Learn more about AVXL's blarcamesine and SAVA's simufilam ...

Cassava Sciences' stock is highly shorted, with potential reward tied to the upcoming Phase 3 trial results for simufilam.

Here is how Cassava Sciences, Inc. (SAVA) and biote Corp. (BTMD) have performed compared to their sector so far this year.

Cassava Sciences, Inc. (NASDAQ:SAVA) Q3 2024 Earnings Call Transcript November 7, 2024 Cassava Sciences, Inc. beats earnings ...

Cassava Sciences, Inc. (SAVA) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the ...

Today, Benzinga's options scanner spotted 8 options trades for Cassava Sciences. This isn't normal. The overall sentiment of ...

STAT+ subscribers can sign up here to get it delivered to their inbox. As we count down toward the December readout of ...